What is the specific efficacy and role of acalatinib/acalatinib?

Acalabrutinib (Acalabrutinib) is a new generation oral Bruton's tyrosine kinase (BTK) inhibitor that is widely used to treat a variety of B cell-related hematological malignancies. Its efficacy in diseases such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) has attracted global attention from the medical community. Its main mechanism of action is to highly selectively inhibit the BTK pathway, interfere with the transmission of B cell receptor signals, prevent the proliferation and survival of malignant B cells, and avoid extensive inhibition of other kinases, thereby reducing the incidence of side effects while maintaining the therapeutic effect.

Compared with the early BTK inhibitor ibrutinib (Ibrutinib), acotinib has higher selectivity and lower incidence of adverse reactions, especially in the control of high-risk complications such as arrhythmia and bleeding. Because of this, it has gradually become one of the first-line drug options to replace ibrutinib in overseas clinical practice. Acotinib is not only suitable for newly treated patients, but also for relapsed and refractory patients who have failed to respond to previous treatments or have developed resistance, which makes it highly flexible in actual treatment. Especially in the treatment of chronic lymphocytic leukemia, the drug has shown effectiveness in people with high-risk genetic mutations and has advantages in extending progression-free survival.

The treatment concept of acotinib emphasizes target precision and sustained inhibition. Its twice-daily dosing regimen helps maintain a stable concentration in the body and achieve a more lastingBTK inhibitory effect. During use, patients can usually achieve significant tumor control effects without the need for chemotherapy drugs, which provides a new option for patients who wish to adopt a "chemotherapy-free" regimen. In addition, acotinib also shows good tolerance, and most adverse reactions are mild. Common ones include headache, fatigue, muscle soreness, etc., which can generally be relieved without interrupting treatment.

Reference materials:https://www.calquence.com/